The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis
World Journal of Surgical Oncology, 08/10/2012
Evidence Based Medicine
Bozcuk H et al. – The authors think that patients with stage 3 non–small–cell lung cancer (NSCLC) are served better with neoadjuvant chemotherapy (NCT) before surgery if protocols with three chemotherapy agents or equally effective combinations are used. In addition, the effect of neoadjuvant chemotherapy is consistent with regard to disease and patient characteristics. This finding should be tested in future randomized clinical trials (RCTs) or individual patient data meta–analyses.
